Online inquiry

IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ854MR)

This product GTTS-WQ854MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ854MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13509MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ1058MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ6162MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ13802MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ9809MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ1055MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ7669MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ2716MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG103
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW